Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Segal Lloyd Mitchell | PRESIDENT AND CEO | Apr 01 '24 | Sale | 4.63 | 2,491 | 11,533 | 107,558 | Apr 01 09:31 PM | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Apr 01 '24 | Sale | 4.61 | 789 | 3,637 | 44,775 | Apr 01 09:30 PM | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Apr 01 '24 | Sale | 4.66 | 410 | 1,911 | 71,908 | Apr 01 09:28 PM | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Apr 01 '24 | Sale | 4.66 | 300 | 1,398 | 231,409 | Apr 01 09:27 PM | Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 28 '24 | Sale | 4.62 | 2,650 | 12,243 | 110,049 | Apr 01 09:31 PM | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 28 '24 | Sale | 4.62 | 825 | 3,812 | 45,564 | Apr 01 09:30 PM | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Mar 28 '24 | Sale | 4.64 | 500 | 2,320 | 231,709 | Apr 01 09:27 PM | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 28 '24 | Sale | 4.64 | 450 | 2,088 | 72,318 | Apr 01 09:28 PM | Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 27 '24 | Sale | 4.63 | 2,650 | 12,270 | 83,866 | Mar 27 06:54 PM | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 27 '24 | Sale | 4.62 | 825 | 3,812 | 42,212 | Mar 27 06:59 PM | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Mar 27 '24 | Sale | 4.62 | 500 | 2,310 | 232,209 | Mar 27 06:56 PM | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 27 '24 | Sale | 4.62 | 450 | 2,079 | 72,768 | Mar 27 06:57 PM | Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 26 '24 | Sale | 4.64 | 2,650 | 12,296 | 86,516 | Mar 27 06:54 PM | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 26 '24 | Sale | 4.60 | 825 | 3,795 | 43,037 | Mar 27 06:59 PM | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Mar 26 '24 | Sale | 4.60 | 500 | 2,300 | 232,709 | Mar 27 06:56 PM | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 26 '24 | Sale | 4.61 | 450 | 2,074 | 73,218 | Mar 27 06:57 PM | Segal Lloyd Mitchell | PRESIDENT AND CEO | Mar 25 '24 | Sale | 4.79 | 2,650 | 12,694 | 89,166 | Mar 27 06:54 PM | Forte Steve | EVP, CHIEF FINANCIAL OFFICER | Mar 25 '24 | Sale | 4.79 | 825 | 3,952 | 43,862 | Mar 27 06:59 PM | Koehler Maria | EVP, CHIEF MEDICAL OFFICER | Mar 25 '24 | Sale | 4.78 | 500 | 2,390 | 233,209 | Mar 27 06:56 PM | Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER | Mar 25 '24 | Sale | 4.78 | 450 | 2,151 | 73,668 | Mar 27 06:57 PM | Koehler Maria | EVP, Chief Medical Officer | Dec 11 '23 | Option Exercise | 2.26 | 43,746 | 98,755 | 219,709 | Dec 12 04:19 PM | BVF PARTNERS L P/IL | 10% Owner | Nov 16 '23 | Buy | 5.38 | 295,745 | 1,592,202 | 5,309,432 | Nov 17 04:54 PM | BVF PARTNERS L P/IL | 10% Owner | Nov 15 '23 | Buy | 5.00 | 931,556 | 4,657,687 | 5,155,739 | Nov 17 04:54 PM | BVF PARTNERS L P/IL | 10% Owner | Nov 02 '23 | Buy | 3.60 | 783,709 | 2,821,352 | 4,662,402 | Nov 03 05:37 PM | Zinda Michael | EVP, Chief Scientific Officer | Jun 07 '23 | Sale | 12.03 | 6,404 | 77,040 | 62,987 | Jun 09 04:25 PM | Zinda Michael | EVP, Chief Scientific Officer | Jun 06 '23 | Sale | 12.04 | 1,200 | 14,448 | 69,391 | Jun 07 04:55 PM |
|